Phase 1 Trial of Autologous HER2-specific CAR T cells in Pediatric Patients with Refractory or Recurrent Ependymoma

Is this Study for You?

Let's Get Started!


Because of your cancer diagnosis, we previously received your permission to make HER2 CAR T cells from the blood you provided. Now, because we have successfully made your HER2 CAR T cells, you will be asked to enroll on the Phase 1 treatment study. The treatment for the Phase 1 study will be given in two parts called (1) Lymphodepletion and (2) HER2 CAR T cell Infusion, which are described in detail in this document. Lymphodepletion consists of treatment with two chemotherapy (anti-cancer) drugs called cyclophosphamide and fludarabine, although in this study we are not using them to treat your cancer. In this study, lymphodepletion is being used to temporarily clear away some of the other immune cells in your blood to make room for the CAR T cells to multiply after we give them. This treatment will be given up to three times. The treatment on this study takes up to one year.




Please visit with your provider for detailed eligibility criteria.

Type of Study



Childrens Hospital Colorado

Principal Investigator
Photograph of Kathleen Dorris,  MD

Kathleen Dorris, MD

Study ID

Protocol Number: 21-5057

More information available at NCT04903080


Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers